Coelho Rogerio Vivaldi - 18 Feb 2022 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
PRESIDENT AND CEO, Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Feb 2022
Net transactions value
+$340,400
Form type
4
Filing time
22 Feb 2022, 16:00:47 UTC
Previous filing
04 Jan 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $340,400 +230,000 $1.48 230,000 18 Feb 2022 Common Stock 230,000 $1.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.